< Back to Team Overview


Dr. George Morstyn

Investment Committee Member

Dr Morstyn has extensive experience in drug development and biotechnology. He was head of the clinical program at the Ludwig Institute for Cancer Research in Melbourne and Principal Investigator on the earliest clinical studies of haemopoietic growth factors. From 1991 to 2002, Dr Morstyn worked for Amgen, rising to Senior Vice President of Development and Chief Medical Officer in 1999.


Dr Morstyn is Chair of the Board of GBS Bioventures and continues as an Investment Committee Member, Deputy Chair of the Victorian Comprehensive Cancer Centre, board member and chair of the scientific advisory board of Symbio (Japan), board member of Proacta, Therapeutic Innovation Australia and a member of the scientific advisory committee of Circadian. He is a member of the commercialisation committee at the Walter and Eliza Hall Institute and the Consultative Council of the Victorian Cancer Agency.